Skip to main content

Advertisement

Table 1 Baseline characteristics of patients with rheumatoid arthritis treated with pelubiprofen or celecoxib

From: Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase III, non-inferiority clinical trial

Variable Pelubiprofen (n =77) Celecoxib (n =68)
Age (mean ± SD, year) 54.3 ± 11.4 54.8 ± 10.8
Female sex, no. (%) 69 (89.6) 62 (91.2)
Disease duration (mean ± SD, month) 100.2 ± 104.2 89.8 ± 88.1
ACR functional class   
  Class I, no. (%) 25 (32.5) 24 (35.3)
  Class II, no. (%) 45 (58.4) 40 (58.8)
  Class III, no. (%) 7 (9.1) 4 (5.9)
  Class IV, no. (%) 0 (0.0) 0 (0.0)
DMARD use, no. (%) 55 (71.4) 47 (69.1)
Prednisolone use, no. (%) 54 (70.1) 42 (61.8)
  1. ACR, American College of Rheumatology; DMARD, disease-modifying anti-rheumatic drug.
  2. P values were determined using the Student t-test or the χ2 test.